S

Sanofi

Global pharma company; vaccines and R&D

Senior GRA Labeling Specialist

Full-TimeUpdated on 10/2/2026Deadline 10/30/26
No salary listed
Senior, Expert
Bachelor's
Hyderabad, Telangana, India
Hybrid

About the job

Requirements
  • Knowledge of labeling principles and concepts, including generics, authorized generics, private labels, and device or combination products, and understanding of labeling team objectives.
  • Knowledge of drug labeling requirements for CCDS EU and US.
  • Ability to coordinate discussions across multifunctional groups and teams to resolve labeling topics.
  • Ability to read and interpret health authority regulations and guidance and relevant company standard operating procedures.
  • Ability to lead multidisciplinary labeling working groups, develop labeling strategy proposals, negotiate, resolve conflicts, and build consensus.
  • Ability to connect labeling strategy with regulatory strategy.
  • Ability to work autonomously on most tasks and seek oversight for complex topics.
  • 10–12 years of relevant experience demonstrating advanced capability.
  • Exposure to working with Regulatory Affairs, Pharmacovigilance, Medical Affairs, or clinical development.
  • Ability to support local countries as a global labeling subject matter expert during labeling negotiations and health authority discussions.
  • Ability to construct company responses to health authority questions related to labeling in the EU and US.
  • Excellent written and verbal communication skills.
  • Situational awareness, leadership, and problem-solving skills.
  • Organizational skills and ability to manage multiple projects at short notice.
  • Ability to work with associates and direct management at all company levels, domestically and internationally.
  • Detail orientation, analytical and organizational skills, project management skills, self-direction, critical thinking, networking, and coordination skills.
  • Ability to build or learn scientific knowledge, such as statistics and disease areas, to work across therapeutic areas.
  • Ability to search for public data on labeling elements using digital capabilities.
  • Bachelor’s degree in a scientific discipline, or relevant/equivalent education with five years of Regulatory Affairs experience, including two years of direct labeling experience, or equivalent experience in a highly regulated environment.
  • Fluent business English.
Responsibilities
  • Lead labeling strategy and prepare or update corporate labeling documents, including CCDS, USPI, EU SmPC, and corresponding patient text, for assigned marketed and lifecycle products and obtain company or agency approval.
  • Coordinate labeling review and approval throughout the end-to-end labeling process, including preparing labeling components for regulatory submissions, participating in agency negotiations that result in product approvals or labeling updates, and releasing labeling for company use for marketed and lifecycle products.
  • Support cross-functional teams as an experienced labeling expert and contribute to global regulatory strategy and preparation of labeling components for submission dossiers or health authority responses.
  • Chair multidisciplinary labeling working groups, present labeling proposals, develop consensus, and present proposals to the Labeling Governance Committee for internal approval.
  • Support maintenance and compliance of existing marketing authorizations as a member of response teams for procedures such as European arbitrations or referrals, work sharing, and PRAC questions related to signal detection.
  • Anticipate implementation hurdles, inform the manager, and act to minimize them.
  • Coordinate, create, and present labeling proposals to senior executive management via the Labeling Review Committee.
  • Assess relevant study reports, post-marketing pharmacovigilance data, and other scientific reports to support labeling proposals.
  • Perform labeling competitive and comparator analyses to provide insights.
  • Meet established submission timelines and quality standards for labeling deliverables.
  • Contribute to transversal or process-improvement projects and workstreams across the labeling portfolio.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)